Pallavi Prasad MD DNB
@DrPallaviPrasad
Followers
2K
Following
4K
Media
147
Statuses
2K
Assistant Prof Nephrology @SJHDelhi. @MAMC alumnus @Glomcon fellow 2022-23. @NSMCInternship 2023. Travel enthusiast. Foodie. Book worm. Plant parent.🪴
New Delhi, India
Joined April 2017
Feeling inspired 🤓:super 6 months working with @tvachh on 3 editorials in high impact factor journals: co author in 2, infographic creator in 1 @AJKDonline @KIReports @CJASN
https://t.co/pnAWmVbQBK
https://t.co/ochmm5Y8En
ajkd.org
In the United States, 80% of patient with chronic kidney disease initiate hemodialysis with a central venous catheter (CVC).1 Over the last 2 decades, initiatives from the Center for Medicare and...
11
1
42
Brushed up your TMA knowledge with the latest @KidneyKolumns? 🦉 Test ur knowledge with the #TMA crossword 🧩 ! Solve online at https://t.co/MpnKf0YsFl Download the latest KK edition from @isn_india website for the solution 😀 👉 https://t.co/yHOYPy4f1g
0
4
7
How to deal with TMA in pediatric age group?👶 - What differentials to think of ❓ - When to go with eculizumab?💉 Prof Aditi Sinha & Prof Arvind Bagga from @aiims_newdelhi give an overview of Pediatric TMA Download here for full text https://t.co/6Cbl3FivCY
1
8
10
Now online in @NDTsocial Efficacy and safety of finerenone with SGLT2i in IgAN 🧐 Fin-SGLT2i therapy showed superior proteinuria reduction versus monotherapy in IgAN, with preserved kidney function and good safety. ▶️ https://t.co/laYtrnvr2u
0
26
89
Day 1: https://t.co/SrhYtyKvMA Day 2: https://t.co/u1Pv3KP33d Day 3:
nephjc.com
Day 3 of Kidney Week. Sibeprenlimab and Balcinrenone on NEJM and Lancet, plus a couple of other non-kidneywk studies.
@kidney_boy @ASNKidney As a non-attendee I would like to thank very much #nephjc crew for the daily summaries. I read all 3 of them 😃 @NephroSeeker @hswapnil
1
36
91
SMART-C simultaneous publication in @JAMA_current! Bottom line: Absolute benefits of SGLT2i far exceed any potential harms in people with & without diabetes, and UACR < & >200mg Time to accelerate implementation to improve population health: https://t.co/YLUnA9EJm3
#kidneywk
0
34
100
Rituximab for Relapsing Nephrotic Syndrome in AdultsA Randomized Clinical Trial
jamanetwork.com
This randomized clinical trial assesses the effect of rituximab on disease relapse in adults with frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome.
1
20
50
Doesn't every case of PRAKI🤰 sound like a TMA🚨? #Nephtwitter #Medtwitter #NephX Read this insightful discussion by Dr Arun Prabhahar, Dr Vinod Kumar and @raja_1980 Download full article at https://t.co/p2m8Fi21SF
0
7
8
Confused about what tests to order and how in a suspected TMA case?! Read the excellent article by Dr Valentine Lobo for learning more about diagnostic tests in TMA. Download full edition here: https://t.co/p2m8Fi21SF
0
9
14
Kidney Kolumns, the official newsletter of the Indian Society of Nephrology (ISN), has grown over the past two years into a well-regarded publication featuring academic insights, educational content, and voices from across the nephrology community. To strengthen our editorial
0
8
12
The October edition of Kidney Kolumns is out! A unique and invaluable patient perspective on TMAs is provided by the indomitable @kamaldshah … makes for a must-read for all of us in nephrology - thank you Mr Shah for your contribution!
1
10
32
🚨New edition alert! 🚨 This festive season we aim to shed light on an enigmatic disease "Thrombotic Microangiopathy"🧩 Since we know so little, we had experts from across India contribute to this edition! Download from from @isn_india website or 👇 https://t.co/p2m8Fi21SF
3
19
26
📢Latest edition is live! 🔗Access it at👇 https://t.co/SswskJ2xMx
0
2
4
✨ New Edition Alert! The latest #kidneyKolumns from @isn_india is out! 🌟 🔬 Membranous Nephropathy – uncover the key insights 🧩 Dive into our crossword: "Membrane Mysteries" 🧠 Test your knowledge with the quiz 📊 Unlock the Stat Pearls
1
14
28
Unravel the Membrane Mysteries🕵️♀️@isn_india @drshyambansal @MayuriTrivedi80
@Nair_Sanj @SethiRenalPath Decode the latest edition of the @KidneyKolumns Crossword 🔍 Fill in the grids with your fastest fingers 💨 Winners will get a shout out 🏅 https://t.co/6Cc1svtAja
0
12
19
2
40
118
New in CJASN 📢 Our meta-analysis of 66 CKD trials shows both acute & chronic GFR slope independently predict clinical outcomes Findings support 3-year total slope as the optimal surrogate endpoint for CKD trials @asnpublications: https://t.co/wqDIt7B194
0
30
49
🔔Metformin has always been my first-line antidiabetic! 🟠Not just for its blood sugar magic🍭 ✨ but so many added benefits too! Rarely had to stop it due to side effects 🚫 This infographic nails it! @NephroSeeker
#Metformin #DiabetesCare @NephJC 📊💊❤️
3
7
41
Furosemide versus torsemide: May the highest dose win! Authors glean insights from the TRANSFORM-HF trial. https://t.co/cjFvQJWcJR
@kantsmd
#ASNKidneyNews
#ASNJASN
1
23
72
The characterization of anti-nephrin autoantibodies has fundamentally changed the pathophysiological concept of podocytopathies. Check out our latest review on anti-nephrin in @CKJsocial Felicitas Hengel & @Tobias_B_Huber
https://t.co/f2kusd7dX1
academic.oup.com
ABSTRACT. Recent studies have identified autoantibodies targeting the podocyte protein nephrin in patients with primary podocytopathies such as minimal cha
0
12
33